Who are in the management team of Lactose (India)?

As of March 2023, the management team of Lactose (India) includes Atul Maheshwari (Chairman & Managing Director), S M Maheshwari (Whole Time Director & CFO), and independent directors Pramod Kalani, G K Sarda, and Dhaval J Soni.

As of March 2023, the management team of Lactose (India) includes:<BR><BR>1. Atul Maheshwari - Chairman & Managing Director<BR>2. S M Maheshwari - Whole Time Director & CFO<BR>3. Pramod Kalani - Independent Non-Executive Director<BR>4. G K Sarda - Independent Non-Executive Director<BR>5. Dhaval J Soni - Independent Non-Executive Director<BR><BR>These individuals play key roles in the governance and management of the company.

What does Lactose (India) do?

Lactose (India) Ltd manufactures and trades edible and pharmaceutical grade lactose within the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of 28 Cr and a net profit of 1 Cr, with a market cap of Rs 132 Cr.

Overview: <BR>Lactose (India) Ltd is engaged in the manufacturing and trading of pharmaceutical products, specifically edible and pharmaceutical grade lactose, and operates within the Pharmaceuticals & Biotechnology industry as a micro-cap company.<BR><BR>History: <BR>Lactose (India) Ltd was incorporated in March 1991 as a Public Limited Company. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 28 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 132 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 26.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.83 <BR>Return on Equity: 10.04% <BR>Price to Book: 2.56 <BR><BR>Contact Details: <BR>Address: Survey No 6, Village Poicha (Rania) Savli Vadodara Gujarat : 391780 <BR>Tel: 91-02667-244308/244729 <BR>Email: investor.lactose@gmail.com <BR>Website: http://www.lactoseindia.com

Has Lactose (India) declared dividend?

No Dividend History Available

Who are the peers of the Lactose (India)?

Lactose (India) peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Parnax Lab, Mangalam Drugs, Welcure Drugs, and Samrat Pharma. Lactose (India) has below average management risk, growth, and capital structure compared to its peers, with a 1-year return of -35.55%.

Peers: The peers of Lactose (India) are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Parnax Lab, Mangalam Drugs, Welcure Drugs, and Samrat Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Torrent Pharma, Dr Reddy's Labs, and Samrat Pharma, while Good management risk is found at Divi's Lab. Below Average management risk is noted for Lactose (India), Parnax Lab, Welcure Drugs, and Mangalam Drugs. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Lactose (India), Torrent Pharma, and Mangalam Drugs. Good growth is reported for Parnax Lab, while Average growth is noted for Welcure Drugs and the rest. Capital Structure is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Parnax Lab, while Good capital structure is found at Torrent Pharma. Below Average capital structure is observed for Lactose (India), Mangalam Drugs, and Welcure Drugs.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Lactose (India) has the lowest at -35.55%. Lactose's return is significantly lower than its peers. Additionally, the six-month return is negative for Lactose (India), Sun Pharma.Inds., Torrent Pharma, Dr Reddy's Labs, Parnax Lab, Mangalam Drugs, and Samrat Pharma.

Is Lactose (India) overvalued or undervalued?

As of March 17, 2025, Lactose (India) is considered undervalued with a PE ratio of 25.80 and strong financial metrics, despite a year-to-date stock return of -54.84%, making it an attractive investment compared to peers like Sun Pharma and Cipla.

As of 17 March 2025, Lactose (India) has moved from a fair to an attractive valuation grade, indicating a shift in market perception. The company is currently considered undervalued, supported by a PE ratio of 25.80, an EV to EBITDA of 10.37, and a ROCE of 18.05%. In comparison to its peers, Lactose's valuation metrics stand out; for instance, Sun Pharma has a significantly higher PE ratio of 35.25, while Cipla, another attractive peer, has a PE of 22.99.<BR><BR>Despite recent underperformance, with a year-to-date stock return of -54.84% compared to the Sensex's 5.58%, Lactose (India) presents a compelling investment opportunity given its favorable ratios and the attractive valuation relative to peers like Dr. Reddy's Labs (PE of 19.49) and Zydus Lifesciences (PE of 20.61). This suggests that the market may not fully appreciate Lactose's potential, reinforcing the conclusion that it is undervalued.

What is the technical trend for Lactose (India)?

As of May 26, 2025, Lactose (India) shows a mildly bearish technical trend, with bearish signals from Bollinger Bands and moving averages, despite some mildly bullish indicators in the weekly MACD and KST.

As of 26 May 2025, the technical trend for Lactose (India) has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish trend. The Bollinger Bands are bearish on both weekly and monthly time frames, and daily moving averages are also bearish. The KST presents a mildly bullish signal on the weekly chart but is mildly bearish on the monthly. Dow Theory reflects a mildly bearish outlook on the weekly and a bullish stance on the monthly. Overall, the current technical stance is mildly bearish, influenced by the bearish signals from Bollinger Bands and moving averages, despite some mildly bullish indicators in the MACD and KST on the weekly time frame.

Who are the top shareholders of the Lactose (India)?

The top shareholders of Lactose (India) include Sangita Maheshwari, who holds 30.73%, and Madhusha Holdings Private Limited, the largest public shareholder at 3.97%. Individual investors collectively own 38.31%, with no mutual funds or foreign institutional investors currently involved.

The top shareholders of Lactose (India) include the promoters, who hold a significant majority of the shares. The promoter with the highest holding is Sangita Maheshwari, owning 30.73% of the company. Additionally, Madhusha Holdings Private Limited is the highest public shareholder, holding 3.97%. Individual investors collectively hold 38.31% of the shares, while there are currently no mutual funds or foreign institutional investors (FIIs) involved in the company.

How big is Lactose (India)?

As of 24th July, Lactose (India) Ltd has a market capitalization of 141.00 Cr, with net sales of 116.40 Cr and a net profit of 5.16 Cr in the latest four quarters. The company reported shareholder's funds of 47.10 Cr and total assets of 100.74 Cr for the annual period ending in March 2024.

As of 24th July, Lactose (India) Ltd has a market capitalization of 141.00 Cr, classifying it as a Micro Cap company.<BR><BR>In the latest four quarters, Lactose (India) reported net sales of 116.40 Cr and a net profit of 5.16 Cr.<BR><BR>For the latest annual period ending in March 2024, the company had shareholder's funds amounting to 47.10 Cr and total assets of 100.74 Cr.

When is the next results date for Lactose (India)?

Lactose (India) is scheduled to announce its results on 13 August 2025.

Lactose (India) is scheduled to declare its results on 13 August 2025.

Are Lactose (India) latest results good or bad?

Lactose (India) reported strong net sales growth of 36% and a 37.5% increase in profit before tax for the quarter ending June 2025. However, a 54.18% decline in profit after tax and rising interest expenses indicate challenges, making the overall results mixed.

Lactose (India) has shown a mixed performance in its latest financial results for the quarter ending June 2025. On the positive side, the company reported net sales of Rs 39.58 crore, which is the highest in the last five quarters and represents a significant growth of 36.0% compared to the previous average. Additionally, profit before tax (PBT) increased by 37.5% over the prior four quarters, reaching Rs 1.88 crore.<BR><BR>However, there are notable challenges as well. The profit after tax (PAT) for the latest six months declined by 54.18% year on year, which is concerning. Furthermore, interest expenses have risen to Rs 4.70 crore, indicating increased borrowing costs.<BR><BR>Overall, while there are encouraging signs in terms of sales and PBT growth, the significant drop in PAT and rising interest expenses suggest that the company's financial health is under pressure. Therefore, the results can be viewed as somewhat mixed, with both positive and negative aspects to consider.

How has been the historical performance of Lactose (India)?

Lactose (India) has experienced significant growth, with net sales increasing from INR 34.96 crore in March 2021 to INR 116.40 crore in March 2025, and profit before tax improving from a loss of INR 3.27 crore to a profit of INR 6.92 crore in the same period. Total liabilities rose to INR 133.47 crore, while cash flow from operating activities showed a positive inflow of INR 2.00 crore in March 2025.

Answer:<BR>The historical performance of Lactose (India) shows a significant growth trajectory in net sales and profitability over the years, with net sales increasing from INR 34.96 crore in March 2021 to INR 116.40 crore in March 2025. The total operating income has mirrored this growth, reaching INR 116.40 crore in March 2025, up from INR 34.96 crore in March 2021. The operating profit (PBDIT) has also seen fluctuations, peaking at INR 20.13 crore in March 2024 before slightly declining to INR 18.41 crore in March 2025. Profit before tax has improved from a loss of INR 3.27 crore in March 2021 to a profit of INR 6.92 crore in March 2025, while profit after tax followed a similar trend, rising from a loss of INR 2.48 crore in March 2021 to INR 5.16 crore in March 2025. <BR><BR>In terms of expenses, raw material costs have increased significantly, reaching INR 60.51 crore in March 2025, which reflects the rising operational scale. The company’s total liabilities have grown from INR 84.00 crore in March 2020 to INR 133.47 crore in March 2025, indicating increased borrowing, particularly in short-term borrowings, which rose to INR 30.31 crore in March 2025. Total assets have also increased, reaching INR 133.47 crore in March 2025, supported by a rise in current assets, particularly inventories and sundry debtors. Cash flow from operating activities has remained stable, with a notable cash inflow of INR 2.00 crore in March 2025, compared to a net outflow in previous years. Overall, Lactose (India) has demonstrated resilience and growth in its financial performance over the past several years.<BR><BR>Breakdown:<BR>Lactose (India) has shown a robust growth pattern in its financial metrics over the years. Net sales surged from INR 34.96 crore in March 2021 to INR 116.40 crore in March 2025, reflecting a strong upward trend. Total operating income followed suit, reaching INR 116.40 crore in March 2025. Operating profit (PBDIT) peaked at INR 20.13 crore in March 2024 but slightly declined to INR 18.41 crore in March 2025. Profit before tax improved significantly from a loss of INR 3.27 crore in March 2021 to a profit of INR 6.92 crore in March 2025, while profit after tax rose from a loss of INR 2.48 crore in March 2021 to INR 5.16 crore in March 2025. The company’s total liabilities increased to INR 133.47 crore in March 2025, driven by higher short-term borrowings, while total assets also grew to INR 133.47 crore, supported by rising inventories and sundry debtors. Cash flow from operating activities remained stable, with a net cash inflow of INR 2.00 crore in March 2025, indicating improved liquidity and operational efficiency.

Should I buy, sell or hold Lactose (India) Ltd?

Which are the latest news on Lactose (India)?

Which are the latest news on Lactose (India)?

Why is Lactose (India) falling/rising?

As of 22-Dec, Lactose (India) Ltd's stock price is at 111.95, down 6.44%, and has underperformed the sector. The stock has seen a significant decline over the past year, down 51.52%, despite previous strong performance over the last few years.

As of 22-Dec, Lactose (India) Ltd's stock price is falling, currently at 111.95, which reflects a decrease of 7.7 or 6.44%. The stock has underperformed compared to the sector by 7.09% today and has experienced a trend reversal, falling after two consecutive days of gains. Additionally, the stock reached an intraday low of Rs 108.7, marking a decline of 9.15%. <BR><BR>Over the past week, the stock has decreased by 2.82%, while the benchmark Sensex has increased by 0.42%. In the last month, Lactose (India) has seen a significant decline of 11.57%, contrasting with a slight gain of 0.39% in the Sensex. Year-to-date, the stock has plummeted by 48.15%, while the Sensex has risen by 9.51%. This trend continues over the past year, with Lactose (India) down 51.52% compared to the Sensex's gain of 9.64%. <BR><BR>Despite a strong performance over the last three and five years, where the stock increased by 105.60% and 362.60% respectively, the recent performance indicates a troubling decline. The stock's moving averages show it is higher than the 200-day moving average but lower than the 5-day, 20-day, 50-day, and 100-day moving averages, suggesting a bearish trend. Furthermore, while there has been a rise in investor participation, with delivery volume increasing by 18.08% against the 5-day average, the overall market sentiment appears negative, contributing to the stock's decline.

Why is Lactose (India) Ltd falling/rising?

As of 24-Dec, Lactose (India) Ltd's stock price is Rs 105.00, reflecting a decline of -4.2% and a total drop of -12.24% over the last three days. The stock has significantly underperformed the market, with a year-to-date decrease of -51.37%, compounded by weak fundamentals and bearish trading indicators.

As of 24-Dec, Lactose (India) Ltd is experiencing a decline in its stock price, currently at Rs 105.00, which reflects a change of -4.6 (-4.2%). The stock has been underperforming significantly, with a consecutive fall over the last three days, resulting in a total decline of -12.24% during this period. This trend is compounded by the fact that the stock has underperformed the sector by -3.77% today.<BR><BR>In terms of broader performance, Lactose (India) Ltd has shown a substantial decrease over various time frames, including a -19.14% drop over the past month and a staggering -51.37% year-to-date. Comparatively, the benchmark Sensex has shown positive returns of +0.60% for the month and +9.30% year-to-date, highlighting the stock's significant underperformance against the market.<BR><BR>The stock's current trading position is also concerning, as it is below all major moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), indicating a bearish trend. Additionally, while there has been an increase in investor participation, with delivery volume rising by 67.42% against the 5-day average, this has not translated into positive price movement.<BR><BR>Several negative factors contribute to the stock's decline, including weak long-term fundamental strength, as evidenced by a low average Return on Capital Employed (ROCE) of 9.74% and a high Debt to EBITDA ratio of 3.54 times, which indicates a low ability to service debt. Furthermore, 26.07% of promoter shares are pledged, which can exert additional downward pressure on the stock in a falling market. Overall, these factors collectively explain the current downward trend in Lactose (India) Ltd's stock price.

Why is Lactose (India) Ltd falling/rising?

As of 25-Dec, Lactose (India) Ltd's stock price is Rs 105.00, down 4.2%, with a significant decline of 51.37% year-to-date. The stock has underperformed the benchmark Sensex and is currently trading below its moving averages, indicating bearish sentiment despite increased investor participation.

As of 25-Dec, Lactose (India) Ltd's stock price is falling, currently at Rs 105.00, which reflects a decrease of Rs 4.6 or 4.2%. The stock has been underperforming significantly, with a decline of 7.81% over the past week and 19.14% over the past month, while the benchmark Sensex has shown positive returns of 1.00% and 0.60% respectively during these periods. Year-to-date, the stock has plummeted by 51.37%, contrasting sharply with the Sensex's gain of 9.30%.<BR><BR>Today, the stock has experienced a consecutive fall for the last three days, resulting in a total drop of 12.24% during this period. The day's trading saw the stock reach a high of Rs 112.75 but ultimately closed lower, indicating a significant intraday decline. Furthermore, Lactose (India) is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals bearish sentiment.<BR><BR>Despite a rise in investor participation, with a notable increase in delivery volume, the overall performance remains weak, as the stock has underperformed its sector by 3.77%. This combination of factors contributes to the ongoing decline in Lactose (India) Ltd's stock price.